Caspofungin after solid organ transplantation in Germany : Observational study on treatment of invasive fungal infections;Caspofungin nach Transplantation solider Organe in Deutschland : Beobachtungsstudie zur Behandlung invasiver Pilzinfektion

Anaesthesist

Volumn 59, Issue 12, 2010, Pages 1083-1090

  Lichtenstern, C ^a   Pratschke, J ^b   Schulz, U ^c   Schmoeckel, M ^d   Knitsch, W ^e   Kaskel, P ^f   Krobot, K J ^f   Weigand, M A ^a,g   Winkler, M ^e  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f MSD Sharp and Dohme GmbH   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Aspergillus; Candida; Caspofungin; Fungal infection; Transplantation

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; APACHE; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; DRUG SAFETY; FEMALE; GERMANY; HEART TRANSPLANTATION; HUMAN; INTENSIVE CARE; LIVER TRANSPLANTATION; MALE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OVERALL SURVIVAL; POPULATION; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; SCORING SYSTEM; SURVIVAL RATE; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79451469237     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-010-1795-6     Document Type: Article

References (29)

1. Ascioglu S, Rex JH, De Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14
2. Cornely OA, Lasso M, Betts R et al (2007) Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60:363-369
3. Cruciani M, De Lalla F, Mengoli C (2005) Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 31:1479-1487
4. Denning DW (2003) Echinocandin antifungal drugs. Lancet 362:1142-1151
5. Dinubile MJ, Lupinacci RJ, Strohmaier KM et al (2007) Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 22:237-244
6. Fortun J, Martin-Davila P, Moreno S et al (2002) Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 8:1065-1070
7. Gavalda J, Len O, San JR et al (2005) Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 41:52-59
8. Groetzner J, Kaczmarek I, Wittwer T et al (2008) Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 27:1-6
9. Hagerty JA, Ortiz J, Reich D et al (2003) Fungal infections in solid organ transplant patients. Surg Infect (Larchmt) 4:263-271
10. Husain S, Tollemar J, Dominguez EA et al (2003) Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75:2023-2029
11. Kontoyiannis DP, Boktour M, Hanna H et al (2005) Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 103:2334-2337
12. Kontoyiannis DP, Hachem R, Lewis RE et al (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98:292-299
13. Kontoyiannis DP, Ratanatharathorn V, Young JA et al (2009) Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 11:89-93
14. Linden P, Williams P, Chan KM (2000) Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 14:329-339
15. Maertens J, Raad I, Petrikkos G et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39:1563-1571
16. Marik PE (2006) Fungal infections in solid organ transplantation. Expert Opin Pharmacother 7:297-305
17. MSD, Sharp & Dohme GmbH (Haar, Juli 2009) Fachinformation CANCIDAS® 50 mg/70 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
18. Pappas PG (2005) Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. Clin Infect Dis 40 [Suppl 6]:379-383
19. Patel R, Portela D, Badley AD et al (1996) Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 62:926-934
20. Petrovic J, Ngai A, Bradshaw S et al (2007) Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc 39:3117-3120
21. Playford EG, Webster AC, Sorell TC et al (2004) Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev:CD004291
22. Popp AI, White MH, Quadri T et al (1999) Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study. Int J Infect Dis 3:157-160
23. Salavert M (2008) Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients? Int J Antimicrob Agents 32 [Suppl 2]:149-153
24. Silveira FP, Husain S (2007) Fungal infections in solid organ transplantation. Med Mycol 45:305-320
25. Singh N (2004) Antifungal prophylaxis in solidorgan transplant recipients: considerations for clinical trial design. Clin Infect Dis 39 [Suppl 4]:200-206
26. Singh N, Avery RK, Munoz P et al (2003) Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 36:46-52
27. Singh N, Limaye AP, Forrest G et al (2006) Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81:320-326
28. Singh N, Wagener MM, Marino IR et al (2002) Trends in invasive fungal infections in liver transplant recipients: correlation with evolution in transplantation practices. Transplantation 73:63-67
29. Winkler M, Pratschke J, Schulz U et al (2010) Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study. Transpl Infect Dis 12:230-237